3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Phase 1/2
1
Phase 1
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Conditions
Uterine Cervical Neoplasms
1
Rhabdomyosarcoma
1
Pinealoma
1
Neuroectodermal Tumors, Primitive
1
Neuroblastoma
1
Neoplasms
1
Metastatic Pancreatic Adenocarcinoma
1
Medulloblastoma
1
Central Nervous System Neoplasms
1
Interventions
pembrolizumab
17
Cisplatin
11
Carboplatin
9
Cyclophosphamide
8
fludarabine
6
Paclitaxel
6
Nivolumab
6
Bevacizumab
6
aldesleukin
5
Radiotherapy
5
toripalimab
4
tisotumab vedotin
4
fludarabine phosphate
4
Topotecan
4
Interleukin-2
4
Docetaxel
4
Brachytherapy
4
spartalizumab
3
Ipilimumab
3
Fulvestrant
3
ferumoxtran-10
2
enzalutamide
2
durvalumab
2
cemiplimab
2
bemarituzumab
2
balstilimab
2
Trastuzumab
2
Radiation
2
Magnetic Resonance Spectroscopy
2
Injections
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
Uterine Cervical Neoplasms
×
adavosertib
×
Clear all
NCT01076400
2023-09-18
MK-1775-008
Merck Sharp & Dohme LLC
Phase 1/2
Terminated
7 enrolled
6 charts